Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Preliminary Phase Ib/II Data supports the controllable Safety and encouraging Efficacy in Patients with relapsed/refractory (R/R) diffuse large B-Cell Lymphoma (DLBCL)

被引：0
|
作者：
Hutchings, M. [1 ]
Sureda, A. [2 ]
Terol, M. J. [3 ]
Bosch, F. [4 ]
Corradini, P. [5 ,6 ]
Stauffer, Larsen T. [7 ]
Rueda, Dominguez A. [8 ]
Panchal, A. [9 ]
Bottos, A. [10 ]
Carlile, D.
Wang, Y. [11 ]
de L'Etang, Filezac A. [10 ]
Tandon, M.
Sellam, G. [10 ]
Gritti, G. [12 ]
机构：
[1] Rigshosp, Copenhagen, Denmark
[2] Inst Catala Oncol Hosp, Barcelona, Spain
[3] Univ Valencia, Hosp Clin Univ INCLIVA, Valencia, Spain
[4] Univ Hosp Vall Hebron, Barcelona, Spain
[5] Univ Milan, Milan, Italy
[6] Fondazione IRCCS Ist Nazl Tumori, Milan, Italy
[7] Odense Univ Hosp, Odense, Denmark
[8] Reg & Virgen Victoria Univ Hosp, Malaga, Spain
[9] Roche Prod Ltd, Welwyn Garden City, Herts, England
[10] F Hoffmann Roche Ltd, Basel, Switzerland
[11] F Hoffmann Roche Ltd, Shanghai, Peoples R China
[12] Ospedale Papa Giovanni 23, Bergamo, Italy
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V195
引用
收藏
页码：54 / 54
页数：1
相关论文
共 50 条
  • [21] Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma
    Lu, Tong
    Gibiansky, Leonid
    Li, Xiaobin
    Li, Chunze
    Shi, Rong
    Agarwal, Priya
    Hirata, Jamie
    Miles, Dale
    Chanu, Pascal
    Girish, Sandhya
    Jin, Jin Yan
    Lu, Dan
    LEUKEMIA & LYMPHOMA, 2020, 61 (12) : 2905 - 2914
  • [22] A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Hertzberg, Mark
    Ku, Matthew
    Catalani, Olivier
    Althaus, Betsy
    Simko, Stephen
    Gregory, Gareth P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [23] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
    Dyer, Martin J. S.
    De Vos, Sven
    Ruan, Jia
    Flowers, Christopher
    Maddocks, Kami J.
    Rule, Simon
    Hamdy, Ahmed M.
    Izumi, Raquel
    Slatter, J. Greg
    Cheung, Jean
    Frigualt, Melanie M.
    Wei, Helen
    Mourya, Sanchita
    Hunder, Naomi N. H.
    Fowler, Nathan Hale
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [24] Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
    Olszewski, Adam J.
    Budde, L. Elizabeth
    Chavez, Julio
    Ghosh, Nilanjan
    Kamdar, Manali
    Lossos, Izidore S.
    Diefenbach, Catherine
    Sabry, Waleed
    Dorritie, Kathleen
    Huw, Ling-Yuh
    Pham, Song
    Jia, Ting
    Wu, Hao
    To, Iris
    Wei, Michael C.
    Assouline, Sarit
    BLOOD, 2022, 140 : 3757 - 3758
  • [25] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
  • [26] Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab
    Amaya, M. L.
    Jimeno, A.
    Kamdar, M.
    DRUGS OF TODAY, 2020, 56 (04) : 287 - 294
  • [27] Pola-R-ICE: Results from the Interim Safety Analysis. Polatuzumab-vedotin in combination with rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) compared to R-ICE as salvage therapy in patients with primary refractory or relapsed diffuse large B-cell lymphoma (DLBCL)
    van Heteren, P.
    Saidy, Ossami A.
    Michael, R.
    Altmann, B.
    Davies, A.
    Greil, R.
    Garcia-Sancho, A. M.
    Kerkoff, A.
    Kroschinsky, F.
    Vicente, de la Cruz F.
    Haenel, M.
    Schnetzke, U.
    Polowinski, A.
    Koehler, C.
    Ziepert, M.
    Glass, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 108 - 109
  • [28] Polatuzumab vedotin in combination with rituximab and bendamustine (Pola-RB) for relapsed primary cutaneous diffuse large B-cell lymphoma
    Wilms, L.
    Oymanns, M.
    Huenerlituerkoglu, A.
    Dippel, E.
    Assaf, C.
    EUROPEAN JOURNAL OF CANCER, 2022, 173 : S25 - S25
  • [29] Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized Study
    Sehn, Laurie H.
    Matasar, Matthew J.
    Flowers, Christopher R.
    Kamdar, Manali
    McMillan, Andrew K.
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Croft, Brandon
    Hirata, Jamie
    Cheng, Ji
    Ku, Grace
    Herrera, Alex F.
    BLOOD, 2019, 134
  • [30] A Phase Ib Open-Label Study of MRG001 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
    Zhu, Jun
    Song, Yuqin
    Guo, Ye
    Zhou, Keshu
    Li, Wenyu
    Yang, Yu
    Cai, Qingqing
    Wang, Zhao
    Yang, Haiyan
    BLOOD, 2023, 142
12345